The Relationship between Inflammation Markers (CRP, IL-6, sCD40L) and Colorectal Cancer Stage, Grade, Size and Location
暂无分享,去创建一个
A. Milewska | J. Kamińska | O. Koper-Lenkiewicz | V. Dymicka-Piekarska | J. Zińczuk | Joanna Kamińska
[1] M. Maciejczyk,et al. Antioxidant Barrier, Redox Status, and Oxidative Damage to Biomolecules in Patients with Colorectal Cancer. Can Malondialdehyde and Catalase Be Markers of Colorectal Cancer Advancement? , 2019, Biomolecules.
[2] A. Milewska,et al. Serum and cerebrospinal fluid Neudesin concentration and Neudesin Quotient as potential circulating biomarkers of a primary brain tumor , 2019, BMC Cancer.
[3] S. Ryu,et al. Mechanisms regulating intestinal barrier integrity and its pathological implications , 2018, Experimental & Molecular Medicine.
[4] Y. Fujiwara,et al. Prognostic value of the combination of pre- and postoperative C-reactive protein in colorectal cancer patients , 2018, Surgery Today.
[5] Christian Dehlendorff,et al. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer , 2018, Oncotarget.
[6] Jun Shen,et al. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. , 2017, Biochemical and biophysical research communications.
[7] M. Antonelli,et al. It's time to redefine inflammation , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] J. Kamińska,et al. Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines. , 2016, Polskie Archiwum Medycyny Wewnetrznej.
[9] W. Chou,et al. Pretreatment serum interleukin‐1β, interleukin‐6, and tumor necrosis factor‐α levels predict the progression of colorectal cancer , 2016, Cancer medicine.
[10] Hiroki Takahashi,et al. Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients , 2015, Gastroenterology research and practice.
[11] E. Giovannucci,et al. Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women , 2015, Cancer Prevention Research.
[12] Bernard Klein,et al. Interleukin-6 as a Therapeutic Target , 2015, Clinical Cancer Research.
[13] S. Pathak,et al. Is C‐reactive protein useful in prognostication for colorectal cancer? A systematic review , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[14] Toshio Tanaka,et al. IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.
[15] H. Kemona,et al. Multifunctional CD40L: pro- and anti-neoplastic activity , 2014, Tumor Biology.
[16] H. Kemona,et al. Potential Role of Soluble CD40 Ligand as Inflammatory Biomarker in Colorectal Cancer Patients , 2014, The International journal of biological markers.
[17] Mikinori Sato,et al. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction , 2013, British Journal of Cancer.
[18] M. Choti,et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[19] J. Schlom,et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. , 2012, Blood.
[20] Naveena Singh,et al. Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.
[21] Yongling Ning,et al. Role of vascular endothelial growth factor receptor in the pro-proliferation activity of CD40-CD40L in AGS gastric cancer cells , 2010 .
[22] Y. DeClerck,et al. Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.
[23] Z. Culig,et al. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells , 2010, Endocrine-related cancer.
[24] M. Matłok,et al. IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[25] C. Hua,et al. Expression of CD40 and CD40L in Gastric Cancer Tissue and Its Clinical Significance , 2009, International journal of molecular sciences.
[26] Chia-Siu Wang,et al. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. , 2009, Chang Gung medical journal.
[27] P. Dunbar,et al. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). , 2009, Neoplasia.
[28] P. Kosmidis,et al. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. , 2009, Anticancer research.
[29] Byung Geun Kim,et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer , 2009, BMC Cancer.
[30] R. Noelle,et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.
[31] M. Karin,et al. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.
[32] M. Karin,et al. Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.
[33] A. Melcher,et al. CD40‐mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumour cell killing , 2007, International journal of cancer.
[34] D. Lawlor,et al. A systematic review of the association between circulating concentrations of C reactive protein and cancer , 2007, Journal of Epidemiology and Community Health.
[35] H. Kemona,et al. Does surgery affect certain mediators of thrombocytopoiesis in patients with colorectal cancer? , 2007, Hepato-gastroenterology.
[36] Chekhun Vf,et al. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. , 2007 .
[37] D. Frank,et al. IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. , 2004, Carcinogenesis.
[38] Stefan Wirtz,et al. TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .
[39] M. Sans,et al. The CD40/CD40L costimulatory pathway in inflammatory bowel disease , 2004, Gut.
[40] N. Konishi,et al. C-Reactive Protein as a Prognostic Variable That Reflects Uncontrolled Up-Regulation of the IL-1-IL-6 Network System in Colorectal Carcinoma , 2004, Digestive Diseases and Sciences.
[41] G. Davı̀,et al. Soluble CD40 Ligand Plasma Levels in Lung Cancer , 2004, Clinical Cancer Research.
[42] C. McArdle,et al. Systemic inflammatory response predicts survival following curative resection of colorectal cancer , 2003, The British journal of surgery.
[43] T. Sieber,et al. Increased expression of CD40 ligand on activated T cells of patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] L. Pelosio,et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. , 2002, Clinical immunology.
[45] T. Nozoe,et al. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. , 2000, American journal of clinical oncology.
[46] Reinhold Förster,et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.
[47] P. Libby,et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? , 1997, Circulation research.
[48] P. Thompson,et al. ACSM's Guidelines for Exercise Testing and Prescription , 1995 .
[49] S. Ishihara,et al. Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients. , 2014, Oncology reports.
[50] R. Küppers. Molecular biology of Hodgkin lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.
[51] H. Kemona,et al. Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. , 2007, Thrombosis research.
[52] A. Caro-Patón Gómez,et al. Interleukins and colon cancer. , 2005, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[53] MariaGazouli,et al. Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications , 2005 .